CMI
56
-2
PLD
41
-4
FLS
38
-2
KO
57
-3
SWKS
53
-2
IVZ
36
-2
WEC
62
-3
WYNN
21
-2
KMB
40
-4
UNM
53
-4
STX
78
-10
EMC
84
-5
APD
42
-2
BMY
43
2
ILMN
45
-4
AN
46
3
OI
32
2
KMI
50
4
EBAY
66
10
QRVO
61
-2
CMI
56
-2
PLD
41
-4
FLS
38
-2
KO
57
-3
SWKS
53
-2
IVZ
36
-2
WEC
62
-3
WYNN
21
-2
KMB
40
-4
UNM
53
-4
STX
78
-10
EMC
84
-5
APD
42
-2
BMY
43
2
ILMN
45
-4
AN
46
3
OI
32
2
KMI
50
4
EBAY
66
10
QRVO
61
-2
Financhill
Back

Diebold Nixdorf 10K Form

Buy
57

DBD
Diebold Nixdorf

Last Price:
$49.99
Seasonality Move:
-9.75%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive DBD News And Ratings

See the #1 stock for the next 7 days that we like better than DBD

DBD Financial Statistics

Sales & Book Value

Annual Sales: $3.8B
Cash Flow: $6.1M
Price / Cash Flow: 12.36
Annual Sales: $26.27
Price / Book: 1.88

Profitability

EPS (TTM): -0.27000
Net Income (TTM): $-10.2M
Gross Margin: $920M
Return on Equity: -1.01%
Return on Assets: -0.27%

Diebold Nixdorf Earnings Forecast

Key Diebold Nixdorf Financial Ratios

  • The Gross Profit Margin over the past 40 years for DBD is 24.53%.
  • The Selling, General & Administrative Expenses for DBD have been equal to 17.16% of Gross Profit Margin.
  • The Research & Development expenses have been 2.50% of Revenue.
  • The Net Earning history of DBD is -0.44% of Total Revenues.
  • Per Share Earnings over the last 40 years have been positive in 20 years.

Diebold Nixdorf Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Technology Hardware, Storage & Peripherals
Sector: Information Technology
Current Symbol: DBD
CUSIP: 253651
Website: dieboldnixdorf.com

Debt

Debt-to-Equity Ratio: 0.94
Current Ratio: 1.35
Quick Ratio: 0.71

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 10.72

DBD Technical Analysis vs Fundamental Analysis

Buy
57
Diebold Nixdorf (DBD) is a Buy

Is Diebold Nixdorf a Buy or a Sell?

  • Diebold Nixdorf stock is rated a Buy
    The current Diebold Nixdorf [DBD] share price is $49.71. The Score for DBD is 57, which is 14% above its historic median score of 50, and infers lower risk than normal.